- Home
- CGTX vs ADAG Comparison
CGTX vs ADAG Comparison
Compare CGTX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- ADAG
- Stock Information
- Founded
- CGTX 2007
- ADAG 2011
- Country
- CGTX United States
- ADAG China
- Employees
- CGTX N/A
- ADAG N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- ADAG Health Care
- Exchange
- CGTX Nasdaq
- ADAG Nasdaq
- Market Cap
- CGTX 126.2M
- ADAG 110.8M
- IPO Year
- CGTX 2021
- ADAG 2021
- Fundamental
- Price
- CGTX $1.70
- ADAG $1.95
- Analyst Decision
- CGTX Strong Buy
- ADAG Strong Buy
- Analyst Count
- CGTX 3
- ADAG 3
- Target Price
- CGTX $2.83
- ADAG $7.67
- AVG Volume (30 Days)
- CGTX 3.3M
- ADAG 60.8K
- Earning Date
- CGTX 11-12-2025
- ADAG 08-12-2025
- Dividend Yield
- CGTX N/A
- ADAG N/A
- EPS Growth
- CGTX N/A
- ADAG N/A
- EPS
- CGTX N/A
- ADAG N/A
- Revenue
- CGTX N/A
- ADAG $103,204.00
- Revenue This Year
- CGTX N/A
- ADAG $7,411.34
- Revenue Next Year
- CGTX N/A
- ADAG $28.29
- P/E Ratio
- CGTX N/A
- ADAG N/A
- Revenue Growth
- CGTX N/A
- ADAG N/A
- 52 Week Low
- CGTX $0.22
- ADAG $1.33
- 52 Week High
- CGTX $3.83
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- CGTX 52.47
- ADAG 44.56
- Support Level
- CGTX $1.29
- ADAG $1.85
- Resistance Level
- CGTX $1.61
- ADAG $2.06
- Average True Range (ATR)
- CGTX 0.14
- ADAG 0.11
- MACD
- CGTX -0.01
- ADAG -0.01
- Stochastic Oscillator
- CGTX 93.62
- ADAG 26.08
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.